NCT06474455View on ClinicalTrials.gov

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

SHR-9839 ；SHR-A2009

SHR-9839 combined with SHR-A2009

DRUG

SHR-9839 ； SHR-A1921

SHR-9839 combined with SHR-A1921

DRUG

SHR-9839 ； pemetrexed ；carboplatin

SHR-9839 combined with pemetrexed + carboplatin

DRUG

SHR-9839 ； Almonertinib

SHR-9839 combined with Almonertinib

Trial Locations (2)

310005

Zhejiang Cancer Hospital, Zhejiang

450003

HeNan CANCER HOSPITAL, Zhenzhou

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

NCT06474455 - A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter